Ignite Creation Date:
2024-05-05 @ 4:56 PM
Last Modification Date:
2024-10-26 @ 9:26 AM
Study NCT ID:
NCT00359450
Status:
TERMINATED
Last Update Posted:
2010-03-02
First Post:
2006-08-01
Brief Title:
Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC Non Small Cell Lung Cancer
Sponsor:
Bristol-Myers Squibb
Organization:
Bristol-Myers Squibb
Study Overview
Official Title:
A Three Cohort Phase II Trial of BMS-275183 Given Orally on a Twice Weekly Schedule in Pretreated Locally Advanced or Metastatic NSCLC Patients
Status:
TERMINATED
Status Verified Date:
2007-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
BMS-275183 given orally twice weekly to patients pretreated for locally advanced or metastatic NSCLC will show anti-tumor activity in any of the 3 separate cohorts of the patients enrolled
Cohort I Patients previously treated with one taxane containing regimen
Cohort II Patients previously treated with a platinum based but non-taxane containing regimen
Cohort III Patients previously treated with both a chemotherapy regimen and one EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor compound
Patients in cohorts I and II should have not been treated with a prior EGFR-TKI compound Prior treatment with a VEGFR vascular endothelial growth factor receptor inhibitor compound is allowed for all the patients provided that the VEGFR inhibitor is not also an EGFR inhibitor
Cohort I Patients previously treated with one taxane containing regimen
Cohort II Patients previously treated with a platinum based but non-taxane containing regimen
Cohort III Patients previously treated with both a chemotherapy regimen and one EGFR-TKI epidermal growth factor receptor-tyrosine kinase inhibitor compound
Patients in cohorts I and II should have not been treated with a prior EGFR-TKI compound Prior treatment with a VEGFR vascular endothelial growth factor receptor inhibitor compound is allowed for all the patients provided that the VEGFR inhibitor is not also an EGFR inhibitor
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| EUDRACT 2005-005099-33 | None | None | None |